Please provide your email address to receive an email when new articles are posted on . Four adnexal mass classification algorithms successfully distinguished lesions when used by a novice operator. A ...

Adnexal tumors are growths near the uterus. They're also known as adnexal masses. They usually form in the ovaries, which make eggs and hormones, or the fallopian tubes, which connect your uterus and ...

Ovarian tumours and adnexal masses encompass a broad spectrum of pathologies, ranging from benign cysts to aggressive malignancies. Accurate and early diagnosis is critical due to the high mortality ...

Three-dimensional power Doppler (3DPD) ultrasound has been used for assessing adnexal masses, and in this study, we aimed to perform a meta-analysis to evaluate its role in the differential diagnosis ...

Current clinical methods used to identify epithelial ovarian cancer are often too late – when the cancer is at an advanced stage, leaving the patient with limited therapeutic options. Diagnosis is ...

Three-dimensional power Doppler (3DPD) ultrasound has been used for assessing adnexal masses, and in this study, we aimed to perform a meta-analysis to evaluate its role in the differential diagnosis ...

Ovarian Cancer is the 9th most common cancer in the world 1, and Europe has the highest rates of ovarian cancer in the world 2. Although the cancer antigen 125 (CA 125) assay has been used for more ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Lesions of the ovary and fallopian tube (collectively, the adnexa) are found in up to 35% of premenopausal and 17% of postmenopausal patients. 1,2 They occur throughout the life cycle, with a spectrum ...

Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non–Small-Cell Lung Cancer Data from 1,066 patients recruited from nine European centers ...

Differences in clinical features between CA-125 and RECIST progression in patients with ovarian cancer treated with PARP inhibitors. Efficacy and safety of envafolimab plus lenvatinib combined with ...